Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers

Completed · Phase 1

Conditions studied: Psoriasis

In brief

Cellceutix Corporation has created a new chemical entity for the treatment of psoriasis, termed Prurisol™, which is an ester of abacavir. This first-in-human study of Prurisol (abacavir acetate) is being performed to evaluate the pharmacokinetics, safety and tolerance of a single oral doses of Prurisol administered to healthy volunteers and the bioequivalence to abacavir sulfate (Ziagen). This study will be followed by a 505(b)(2) Phase 2 trial in patients with moderate to severe plaque psoriasis.

Key facts

Study ID

NCT02101216

Run by

Cellceutix Corporation

People needed

18

Starts

2014-03-01

Expected to finish

2014-10-01

Last updated by the study team

2018-10-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Individuals who meet ALL of the following criteria are eligible for participation in this study:
• Provided written informed consent
• Male or female adult aged 18-65 years old (inclusive). At least 20% of enrolled subjects will be aged 55-65 years, inclusive. Effort will be made to enroll equivalent numbers of males and females
• BMI of 19-32 kg/m2
• Identified as a non-smoker at the Consent/Screening Visit. A urine cotinine test will be performed at screening and during each clinic check-in before for each of the three Treatment Visits
• Willing and able to comply with all aspects of the study protocol including avoiding use of certain concomitant medications and attending the required clinic visits

You may not qualify if…

• Subjects are not eligible for participation in the study if any of the following criteria are met:
• Females of childbearing potential not using reliable contraception, (e.g., abstinence, double barrier method, oral/implantable/transdermal contraception. Depo-provera, intrauterine device)
• Female who is pregnant, lactating, has a positive serum pregnancy test drawn at the Consent/Screening Visit, or has a positive urine pregnancy test at check-in performed prior to any of the 3 Treatment Days
• Presence of any uncontrolled (in the Investigator's medical opinion) systemic disease, including, but not limited to renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or psychiatric disease
• History of any immune disorder, or disease/condition potentially affecting the immune system
• Regular use of oral or parenteral corticosteroids (inhaled corticosteroids for stable asthma or chronic obstructive pulmonary disease are permitted)
• ECG obtained at Consent/Screening Visit which shows medically significant abnormalities (e.g. bundle branch block, frequent premature ventricular contractions, corrected QT interval (QTc) prolongation >450 msec for males and >470 msec for females)
• Presence of a condition that makes it unlikely that the requirements of the protocol will be completed
• Urine screening test(s) positive for evidence of amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, opiates, phencyclidine, marijuana
• Positive urine cotinine test
• Positive breath alcohol test
• History of hypersensitivity to any formulation of abacavir
• Previous treatment with any abacavir-containing product
• Current participation or participation in a drug/device or biologic investigational research study within 30 days prior to the Treatment A Visit
• An elective surgical or medical procedure is planned or scheduled to be performed during the period of the study
• Past surgical history of any degree of gastric resection or gastric banding
• History of a clinically diagnosed upper respiratory tract infection or any acute illness requiring antibiotic therapy within 14 days prior to the Treatment A Visit
• Systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg or heart rate <45 bpm in a subject under the age of 40 years and heart rate <50 bpm in a subject aged ≥40 years or >100 bpm (any subject age) on repeat determinations at the Consent/Screening Visit or at check-in on the day prior to each of the 3 Treatment Days and at pre-dose if drug administered on different day than check-in
• Clinical laboratory results at the Consent/Screening Visit that show any one or more of the following:
• Hemoglobin <11 Gm/dL, Hematocrit<30%
• Total white blood cell count <3000cells/mm3
• Absolute neutrophil count <1500cells/mm3
• Platelet count <100,000/mm3
• alanine aminotransferase or aspartate aminotransferase >1.5 x Upper Limit of Normal (ULN)
• Serum amylase above ULN

Where it is running

• Phase One Solutions Inc. — Miami Gardens, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.